Escudero D, Molina R, Viña L, Rodríguez P, Marqués L, Fernández E, Forcelledo L, Otero J, Taboada F, Vega P, Murias E, Gil A
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
Med Intensiva. 2010 Aug-Sep;34(6):370-8. doi: 10.1016/j.medin.2010.01.010. Epub 2010 Mar 23.
Analysis of the safety and efficacy of intra-arterial thrombolysis therapy and endovascular treatment in acute ischemic stroke. DESIGN AND AREA: An observational prospective study in the Intensive Care Unit.
16 patients had endovascular treatment. Epidemiological data, arterial occlusion site, time between stroke onset and treatment, treatment indication, NIHSS scale at admission and discharge from hospital, complications and functional outcome measured by modified Rankin scale (obtained by telephone survey) were collected.
Ten male patients with a mean age of 59 years (29-74) were included. The mean stay in the ICU was 6 days (1-33). Seven patients required mechanical ventilation. Treatment indications were: intravenous thrombolysis failure in 4 patients, major vessel occlusion in 5, outside of the therapeutic window in 2, posterior circulation occlusion in 3, outside of the therapeutic window plus major vessel occlusion in 1 and intravenous thrombolysis contraindication in 1. The occlusion site was on posterior circulation in 3 and on carotid territories and branches in 13. Thrombolytic treatment used was Urokinase at a dose of 100,000-600,000IU. Four patients required mechanical embolectomy and 10 stent implantation. Complete recanalization was observed in 11 (69%) and partial in 4 (25%). Three evolved to brain death. Six patients (46%) had a favorable outcome (modified Rankin scale score ≤ 2). Technical complication was 1 femoral artery pseudoaneurysm.
With the intra-arterial treatment, high rates of recanalization and favorable outcome are obtained with few complications. It could be indicated in patients with severe neurological injury (NIHSS ≥ 10), evolution time between 3-6h, intravenous thrombolysis contraindication and proximal arterial occlusion.
分析动脉内溶栓治疗及血管内治疗在急性缺血性卒中中的安全性和有效性。
在重症监护病房进行的一项观察性前瞻性研究。
16例患者接受了血管内治疗。收集了流行病学数据、动脉闭塞部位、卒中发作至治疗的时间、治疗指征、入院及出院时的美国国立卫生研究院卒中量表(NIHSS)评分、并发症以及通过改良Rankin量表(通过电话调查获得)测量的功能结局。
纳入10例男性患者,平均年龄59岁(29 - 74岁)。在重症监护病房的平均住院时间为6天(1 - 33天)。7例患者需要机械通气。治疗指征为:4例静脉溶栓失败,5例为大血管闭塞,2例超出治疗窗,3例为后循环闭塞,1例超出治疗窗加大血管闭塞,1例为静脉溶栓禁忌。闭塞部位3例位于后循环,13例位于颈动脉区域及分支。使用的溶栓治疗药物为尿激酶,剂量为100,000 - 600,000IU。4例患者需要进行机械取栓,10例患者进行了支架植入。11例(69%)实现完全再通,4例(25%)部分再通。3例进展为脑死亡。6例患者(46%)预后良好(改良Rankin量表评分≤2)。技术并发症为1例股动脉假性动脉瘤。
通过动脉内治疗,可获得较高的再通率和良好的预后,并发症较少。对于严重神经损伤(NIHSS≥10)、发病时间在3 - 6小时之间、静脉溶栓禁忌以及近端动脉闭塞的患者,可考虑采用该治疗方法。